EGFR and adenocarcinoma: When subgroup analyses were performed by baseline clinical characteristics in forest plots, most subgroups including age ≤58 (95% CI, 0.27 to 0.85), smoking never (95% CI, 0.41 to 0.97), ECOG PS 0-1 (95% CI, 0.33 to 0.77), clinical stage IV (95% CI, 0.40 to 0.89), adenocarcinoma (95% CI, 0.43 to 0.95) and gefitinib or icotinib (95% CI, 0.28 to 0.85), patients treated with EGFR-TKIs plus ginsenoside Rg3 could benefit from clinical outcome.